muscle atrophy muscle wasting Sarcopenia
Conditions
Interventions
Subjects will receive 600 mL of a protein-rich enteral feed (nutritional
supplement: Nutrison Advanced Protison, containing 7.5 g protein, 15.4 g
carbohydrates. and 3.7 g fat per 100 mL) prior to hi
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Osteoarthritis of the hip, planned for operative treatment Age 40-85 yr BMI 18.5 - 35 MNA-score >17
Exclusion criteria
Exclusion criteria: - Co-morbidities and neuromuscular disorders of the lower limbs severely interacting with mobility - Co-morbidities severely interacting with muscle metabolism of the lower limbs - Gastrointestinal disease - Known renal malfunction without documented approval from nephrologist) - Known allergy to milk, milk products and soy - Known galactosaemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Muscle protein-bound L-[ring-13C6]-phenylalanine enrichments (expressed as MPE) - Bone protein-bound L-[ring-13C6]-phenylalanine enrichments (expressed as MPE) - Muscle tissue-free L-[ring-13C6]-phenylalanine enrichments (expressed as MPE) - Bone tissue-free L-[ring-13C6]-phenylalanine enrichments (expressed as MPE) - Plasma L-[ring-13C6]-phenylalanine enrichments (expressed as MPE) | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints will be plasma amino acid concentrations (i.e. total and essential amino acids, leucine, phenylalanine and albumin), and glucose, and insulin concentrations during surgery. | — |
Countries
Netherlands
Outcome results
None listed